Uncategorized

Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% – Investors | Eli Lilly and Company

Posted on Author Comments Off on Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% – Investors | Eli Lilly and Company
  1. Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%  Investors | Eli Lilly and Company
  2. Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says  CNN
  3. Zepbound results in more weight loss than Wegovy in trial, Eli Lilly says  NBC News
  4. Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy  MarketWatch
  5. Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial  Bloomberg